Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy

Federal University of São Paulo

Status and phase: Withdrawn; Phase 4

Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment

Treatments: Other: Triple Therapy

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01666236

CBPD952ABR01T

Details and patient eligibility

About

Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline. Treatment under study is a triple therapy with: 1) reduced-fluence photodynamic therapy (PDT), 2) intravitreal (IVT) triamcinolone and, 3) IVT ranibizumab, for the treatment of detachment of the retinal pigment epithelium (PED) secondary to Polypoidal Choroidal Vasculopathy (PCV).

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with PCV associated with PED near the polypoidal lesion recently diagnosed, documented by FA, ICGA and OCT.
• Visual acuity between 20/40 and 20/400.
• Patients older than 50 years (both genders).
• Women must be postmenopausal for at least 12 months or surgically sterile.
• No previous treatment in the study eye.
• Accept and sign the informed consent.
• No condition that prevents the monitoring of the patient for one year.
• Transparent ocular media and adequate pupillary dilation to allow good images of the fundus.

Exclusion criteria

• Blepharitis or external eye infection.
• Allergy to ranibizumab, verteporfin, triamcinolone, fluorescein or indocyanine green.
• Patients unable to provide informed consent.
• Concomitant ocular disease that impairs visual acuity.
• Any intraocular condition (such as cataract or Proliferative Diabetic Retinopathy) in the study eye, in the opinion of the investigator, could require surgery or medication during the follow-up (1 year).
• Active intraocular inflammation.
• Patients with Glaucoma and with ocular hypertension (IOP > 25mmHg).
• Premenopausal women. Pregnancy or lactation.
• Effective treatment for active systemic infection or history of recurrent infection.
• Evidence of concomitant disease (cardiovascular, neurological, pulmonary, renal, hepatic, endocrine or gastrointestinal) uncontrolled.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Triple Therapy

Other group

Description:

The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day. After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections

Treatment:

Other: Triple Therapy